Current and Future Clinical Cancer Advances

Clinical cancer advances in research are featured in this year’s 2021 ASCO report reflecting progress in various cancers and across prevention and treatment.

Highlights in the Report Cancer Advances:

• Molecular Profiling Drives Progress in GI Cancers.
• Antibody-Drug Conjugate Shows Promise in GI Cancers.
• Pembrolizumab Doubles Time to Disease Progression in Patients With Advanced Colorectal Cancer With DNA Mismatch Repair Deficiency.
• Progress in bringing targeted therapies to patients with earlier-stage disease.
• Biomarker-driven treatment approaches offer more personalized care for lung, colorectal, and gastric cancers.
• Combinations of different therapies extend survival without increasing toxicity.
• A growing number of targeted therapies offer extended survival for more patients with difficult-to-treat cancers.

Research Priorities in Clinical Cancer for 2021

• Develop and Integrate Artificial Intelligence and Deep Learning in Cancer Research
• Identify Strategies That Predict Response and Resistance to Immunotherapies
• Optimize Multimodality Treatment for Solid Tumors
• Increase Precision Medicine Research and Treatment Approaches in Pediatric and Other Rare Cancers
• Optimize Care for Older Adults With Cancer
• Increase Equitable Access to Cancer Clinical Trials
• Reduce Adverse Consequences of Cancer Treatment
• Reduce Obesity’s Impact on Cancer Incidence and Outcomes
• Better Identify Potentially Malignant Lesions and Predict When Treatment is Needed

Problems in Clinical Cancer 2021

The COVID-19 public health emergency threatens to reverse years of momentum in cancer research. Laboratories conducting cancer research have closed, or space has been redirected to COVID-19 research. Clinical trials and cancer advances have halted or slowed, creating a costly loss in research progress and delays in patient access to potentially life-saving treatments.

For more information on promising cancer cell treatments, visit: https://cancer-cell-treatment.com